Cite
Kavvoura FK, Pappa M, Evangelou E, et al. The genetic architecture of type 2 diabetes pharmacotherapy: the emerging genomic evidence. Curr Pharm Des. 2014;20(22):3610-9doi: 10.2174/13816128113196660675.
Kavvoura, F. K., Pappa, M., Evangelou, E., & Ntzani, E. E. (2014). The genetic architecture of type 2 diabetes pharmacotherapy: the emerging genomic evidence. Current pharmaceutical design, 20(22), 3610-9. https://doi.org/10.2174/13816128113196660675
Kavvoura, F K, et al. "The genetic architecture of type 2 diabetes pharmacotherapy: the emerging genomic evidence." Current pharmaceutical design vol. 20,22 (2014): 3610-9. doi: https://doi.org/10.2174/13816128113196660675
Kavvoura FK, Pappa M, Evangelou E, Ntzani EE. The genetic architecture of type 2 diabetes pharmacotherapy: the emerging genomic evidence. Curr Pharm Des. 2014;20(22):3610-9. doi: 10.2174/13816128113196660675. PMID: 24040874.
Copy
Download .nbib